Novonesis has announced a €600 million investment to expand its Patalganga site in India and establish a next-generation enzyme production facility. The state-of-the-art plant is expected to become one of the company’s most advanced production sites globally and is scheduled to be fully operational by 2030.
The investment forms part of Novonesis’ long-term growth strategy and its broader efforts to strengthen production capabilities worldwide. The new facility will significantly increase the company’s enzyme manufacturing capacity, allowing it to respond to rising global demand for biosolutions across several industries. Products manufactured at the expanded Patalganga site will serve applications including biofuels, household care, and food and beverage processing.
According to Ester Baiget, President and CEO of Novonesis, the investment represents an important step in executing the company’s growth strategy while supporting sustainable expansion. The project is also expected to improve Novonesis’ ability to serve customers globally and generate long-term value.
The Patalganga expansion will strengthen the company’s presence closer to customers in India, the Middle East, and Africa. Novonesis considers these markets strategically important, with growth expected to outpace that of developed economies in the coming years. Establishing additional production capacity in India should therefore improve regional supply flexibility while reducing reliance on longer-distance shipments.
Anders Lund, Chief Operating Officer of Novonesis, said expanding global manufacturing capacity remains a priority as demand for biosolutions increases across industries and geographical markets. He added that the Patalganga project is expected to improve production scale, operational resilience, efficiency, and supply flexibility.
The investment is part of a wider expansion program across Novonesis’ global manufacturing network. The company has previously expanded facilities in Rayong, Thailand; Franklinton, North Carolina; Taicang, China; Araucaria, Brazil; and West Allis, Wisconsin. These projects support the company’s previously announced capital expenditure plans and global production strategy.
Sustainability is another major component of the Patalganga development. The facility will incorporate technologies designed to reduce water and energy consumption. Freshwater recycling will lower the site’s freshwater requirements, while integrated heat pumps will reduce energy use. These initiatives are expected to support lower Scope 1 and Scope 2 emissions.
Overall, the €600 million investment strengthens Novonesis’ manufacturing footprint in India while positioning the company to capture growing demand for sustainable enzyme-based biosolutions across emerging markets.
Product & Chemical Commodity Price Impact
The new Patalganga facility should have a positive long-term impact on enzyme availability, particularly for biofuels, food and beverage, and household-care applications. Increased local production could improve regional supply reliability, reduce import dependence, and potentially moderate delivered enzyme costs in India and neighboring markets once the plant becomes operational in 2030. For chemical commodities tracked by ChemAnalyst, the immediate price impact is likely limited because the facility will primarily manufacture specialty biological products rather than bulk chemicals. However, stronger enzyme adoption could gradually support demand for biofuel-related feedstocks and processing chemicals, while reducing logistics-related cost pressures for downstream users.
About ChemAnalyst
Leave a Comment
Comments (0)